1.
Hariri AR, Mattay VS, Tessitore A, Kolachana B, Fera F, Goldman D, Egan MF, Weinberger DR: Serotonin transporter genetic variation and the response of the human amygdala. Science 2002; 297:400–403
2.Stein D: Obsessive-compulsive disorder. Lancet 2002; 360:397–405
3.
Moresco FM, Dieci M, Vita A, Messa C, Gobbo C, Galli L, Rizzo G, Panzacchi A, De Peri L, Invernizzi G, Fazio F: In vivo serotonin 5HT(2A) receptor binding and personality traits in healthy subjects: a positron emission tomography study. Neuroimage 2002; 17:1470–1478
4.
McBride PA, Anderson GM, Hertzig ME, Sweeney JA, Kream J, Cohen DJ, Mann JJ: Serotonergic responsivity in young male adults with autistic disorder: results of a pilot study. Arch Gen Psychiatry 1989; 46:213–221
5.
Cook EHJ, Arora RC, Anderson GM, Berry-Kravis EM, Yan SY, Yeoh HC, Sklena PJ, Charak DA, Leventhal BL: Platelet serotonin studies in hyperserotonemic relatives of children with autistic disorder. Life Sci 1993; 52:2005–2015
6.
Veenstra-VanderWeele J, Kim SJ, Lord C, Courchesne R, Akshoomoff N, Leventhal BL, Courchesne E, Cook EH Jr: Transmission disequilibrium studies of the serotonin 5-HT2A receptor gene (HTR2A) in autism. Am J Med Genet 2002; 114:277–283
7.
Lord C, Rutter M, Le Couteur A: Autism Diagnostic Interview—Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 1994; 24:659–685
8.Busatto GF, Pilowsky LS, Costa DC, Mertens J, Terriere D, Ell PJ, Mulligan R, Travis MJ, Leysen JE, Lui D, Gacinovic S, Waddington W, Lingford-Hughes A, Kerwin RW: Initial evaluation of 123I-5-I-R91150, a selective 5-HT2A ligand for single-photon emission tomography, in healthy human subjects. Eur J Nucl Med 1997; 24:119–124
9.
McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH: A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 1996; 53:1001–1008
10.
Whitaker-Azmita PM: Serotonin and brain development: role in human developmental diseases. Brain Res Bull 2001; 56:479–485
11.
McAlonan GM, Daly E, Kumari V, Critchley HD, van Amelsvoort T, Suckling J, Simmons A, Sigmundsson T, Greenwood K, Russell A, Schmitz N, Happe F, Howlin P, Murphy DGM: Brain anatomy and sensorimotor gating in Asperger’s syndrome. Brain 2002; 127:1594–1606
12.
Murphy DGM, Critchley HD, Schmitz N, McAlonan GM, van Amelsvoort T, Robertson D, Daly E, Rowe A, Russell A, Simmons A, Murphy KC, Howlin P: Asperger syndrome: a proton magnetic resonance spectroscopy study of brain. Arch Gen Psychiatry 2002; 59:885–891
13.
Abi-Dargham A, Zea-Ponce Y, Terriere D, Al-Tikriti M, Baldwin R, Hoffer P, Charney DS, Leysen JE, Laruelle M, Mertens J, Innis RB: Preclinical evaluation of [I-123]R93274 as a SPECT radiotracer for imaging serotonin 5-HT2A receptors. Eur J Pharmacol 1997; 321:285–293
14.
Jones HM, Travis MJ, Mulligan R, Bressan RA, Visvikis D, Gacinovic S, Ell PJ, Kerwin RW, Pilowsky LS: In vivo 5-HT2A receptor blockade by quetiapine: an R91150 single photon emission tomography (SPET) study. Psychopharmacology (Berl) 2001; 157:60–66